source
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
- Flu season this year appears to be affecting teens and young adults more severely, experts sayThe article notes that flu activity this year has already resulted in at least 1.7 million reported cases, and health experts are observing that teenagers and young adults are experiencing higher r…